1. Scrip
  2. >>Business
  3. >>Strategy

Lyndra’s Series E Cash Expected To Get Weekly Risperidone To An FDA Filing

 
• By Joseph Haas

Working for years to develop weekly or monthly oral drugs, Lyndra raises $101m and licenses commercial rights in six nations to Sun Pharma in a deal getting its lead product closer to the finish line.

Money in sack on wooden table
Lyndra raises $101m in private equity cash while awaiting Phase III data

Through years of private equity fund raises and partnerships, Lyndra Therapeutics has been building up its strategy to bring once-weekly or monthly oral medications to the health care system. With a $101m series E fundraising and a related commercial rights alliance with Sun Pharmaceutical Industries Ltd. unveiled on 21 December, the Watertown, MA-based company appears to be getting closer to that goal.

Key Takeaways

  • Drug delivery specialist Lyndra raises $101m in series E cash, with some of the money coming from Sun Pharma in exchange for commercial rights to its lead product candidate.

  • Lyndra will release Phase III PK data for its weekly formulation of risperidone in January

In January, Lyndra plans to release data from a Phase III pharmacokinetic study of LYN-005, its weekly, oral formulation of risperidone (Johnson & Johnson’s Risperdal and generics) and begin work on a Phase III safety study it hopes will report out data in time for a new drug application filing in 2025

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from Business

Gilead Joins Pharma’s US Investment Rush

 
• By Alaric DeArment

The company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.